Presenter: Dr. Kevork Khadarian

Title: OBESITY: NEW FRONTIERS IN PHARMACOLOGIC THERAPIES

Learning Objectives
Upon completion of this activity, participants should be able to:

• Review the prevalence of obesity and its implications in healthcare. ​
• Discuss approved medications prior to 2021 for obesity.​
• Discuss the advent of GLP-1 agonists and future direction of pharmacotherapy for obesity.​
• Review Pharmacotherapy for MASLD (resmetirom)

ATTENDANCE / CREDIT
Text the session code (provided only at the session) to 507-200-3010 within 48 hours of the live presentation to record attendance. All learners are encouraged to text attendance regardless of credit needs. This number is only used for receiving text messages related to tracking attendance. Additional tasks to obtain credit may be required based on the specific activity requirements and will be announced accordingly. Swiping your badge will not provide credit; that process is only applicable to meet GME requirements for Residents & Fellows.

TRANSCRIPT
Any credit or attendance awarded from this session will appear on your Transcript.

For disclosure information regarding Mayo Clinic School of Continuous Professional Development accreditation review committee member(s) and staff, please go here to review disclosures.